The rapidly growing recognition of the role of oncogenic ROS1 fusion proteins in the malignant transformation of multiple cancers, including lung adenocarcinoma, cholangiocarcinoma, and glioblastoma, is driving efforts to develop effective ROS1 inhibitors for use as molecularly targeted therapy. Using a multidisciplinary approach involving small molecule screening in combination with in vitro and in vivo tumor models, we show that foretinib (GSK1363089) is a more potent ROS1 inhibitor than crizotinib (PF-02341066), an ALK/ ROS inhibitor currently in clinical evaluation for lung cancer patients harboring ROS1 rearrangements. Whereas crizotinib has demonstrated promising early results in patients with ROS1-rearranged non-small-cell lung carcinoma, recently emerging clinical evidence suggests that patients may develop crizotinib resistance due to acquired point mutations in the kinase domain of ROS1, thus necessitating identification of additional potent ROS1 inhibitors for therapeutic intervention. We confirm that the ROS1 G2032R mutant, recently reported in clinical resistance to crizotinib, retains foretinib sensitivity at concentrations below safe, clinically achievable levels. Furthermore, we use an accelerated mutagenesis screen to preemptively identify mutations in the ROS1 kinase domain that confer resistance to crizotinib and demonstrate that these mutants also remain foretinib sensitive. Taken together, our data strongly suggest that foretinib is a highly effective ROS1 inhibitor, and further clinical investigation to evaluate its potential therapeutic benefit for patients with ROS1-driven malignancies is warranted. R eceptor tyrosine kinases (RTKs) are critical mediators of extracellular signals that control key cell growth, survival, and motility pathways. Conversely, deregulated and constitutive RTK activation is responsible for the initiation and progression of many cancers. Multiple mechanisms contribute to aberrant RTK activation including chromosomal rearrangements, point mutations, and gene amplification. Oncogenic activation of the orphan RTK c-ros oncogene 1 (ROS1) is observed in a subset of patients with glioblastoma, non-small-cell lung cancer (NSCLC), and cholangiocarcinoma (1-5). In most cases, ROS1 signaling is activated by interchromosomal translocation or intrachromosomal deletion that results in N-terminal ROS1 fusion genes. Several ROS1 kinase fusion proteins have been identified, including the Fused in Glioblastoma-ROS1 (FIG-ROS) that was first discovered in a human glioblastoma cell line (2) and more recently in patients with NSCLC (4), cholangiocarcinoma (3), and serous ovarian carcinoma (6). The SLC34A2-ROS1 (SLC-ROS) fusion is present in a subset of patients with NSCLC (1, 7) and gastric cancer (8). Other ROS1 fusions include CD74-ROS1, EZR-ROS1, LRIG3-ROS1, SDC4-ROS1, and TPM3-ROS1 (5).
The rapidly growing recognition of the role of oncogenic ROS1 fusion proteins in the malignant transformation of multiple cancers, including lung adenocarcinoma, cholangiocarcinoma, and glioblastoma, is driving efforts to develop effective ROS1 inhibitors for use as molecularly targeted therapy. Using a multidisciplinary approach involving small molecule screening in combination with in vitro and in vivo tumor models, we show that foretinib (GSK1363089) is a more potent ROS1 inhibitor than crizotinib (PF-02341066), an ALK/ ROS inhibitor currently in clinical evaluation for lung cancer patients harboring ROS1 rearrangements. Whereas crizotinib has demonstrated promising early results in patients with ROS1-rearranged non-small-cell lung carcinoma, recently emerging clinical evidence suggests that patients may develop crizotinib resistance due to acquired point mutations in the kinase domain of ROS1, thus necessitating identification of additional potent ROS1 inhibitors for therapeutic intervention. We confirm that the ROS1 G2032R mutant, recently reported in clinical resistance to crizotinib, retains foretinib sensitivity at concentrations below safe, clinically achievable levels. Furthermore, we use an accelerated mutagenesis screen to preemptively identify mutations in the ROS1 kinase domain that confer resistance to crizotinib and demonstrate that these mutants also remain foretinib sensitive. Taken together, our data strongly suggest that foretinib is a highly effective ROS1 inhibitor, and further clinical investigation to evaluate its potential therapeutic benefit for patients with ROS1-driven malignancies is warranted. R eceptor tyrosine kinases (RTKs) are critical mediators of extracellular signals that control key cell growth, survival, and motility pathways. Conversely, deregulated and constitutive RTK activation is responsible for the initiation and progression of many cancers. Multiple mechanisms contribute to aberrant RTK activation including chromosomal rearrangements, point mutations, and gene amplification. Oncogenic activation of the orphan RTK c-ros oncogene 1 (ROS1) is observed in a subset of patients with glioblastoma, non-small-cell lung cancer (NSCLC), and cholangiocarcinoma (1) (2) (3) (4) (5) . In most cases, ROS1 signaling is activated by interchromosomal translocation or intrachromosomal deletion that results in N-terminal ROS1 fusion genes. Several ROS1 kinase fusion proteins have been identified, including the Fused in Glioblastoma-ROS1 (FIG-ROS) that was first discovered in a human glioblastoma cell line (2) and more recently in patients with NSCLC (4), cholangiocarcinoma (3) , and serous ovarian carcinoma (6) . The SLC34A2-ROS1 (SLC-ROS) fusion is present in a subset of patients with NSCLC (1, 7) and gastric cancer (8) . Other ROS1 fusions include CD74-ROS1, EZR-ROS1, LRIG3-ROS1, SDC4-ROS1, and TPM3-ROS1 (5) .
Given the recent success of molecularly targeted therapies in treating cancers driven by oncogenic kinases, there is acute clinical momentum to identify inhibitors that selectively target ROS1 fusions. Because the ROS1 and Anaplastic Lymphoma Kinase (ALK) domains are partially homologous, the Food and Drug Administration (FDA)-approved ALK/MET kinase inhibitor crizotinib is being investigated via phase I/II clinical trials for its efficacy in ROS1-driven lung cancer patients (9) . Although early results appear promising, consistent with the clinical experience of crizotinib in patients with ALK-positive lung cancer to date, as well as prior experience with kinase inhibitors in many other malignancies (10) (11) (12) (13) , recent evidence suggests that a subset of patients with crizotinib-treated ROS1 fusion-positive may acquire ROS1 kinase domain mutations that confer drug resistance, thus necessitating alternative therapeutic approaches.
To identify additional and potentially more efficacious ROS1 inhibitors, we used an unbiased, high-throughput kinase inhibitor screening assay and discovered that foretinib (GSK1363089) and Gö6976 are potent inhibitors of ROS1. Foretinib selectively suppresses the growth of the SLC-ROS-driven human NSCLC cell line HCC78 and of FIG-ROS-driven murine cholangiocarcinoma, but not of EGFR-driven NSCLC or phosphatase and tensin homolog (PTEN)-suppressed murine cholangiocarcinoma cells. Further, treatment of tumor-bearing mice with foretinib resulted in specific and dramatic regression of FIG-ROS-driven tumors in contrast to non-FIG-ROS tumors that share similar histopathological features. Importantly, we also use a cell-based in vitro resistance screen to preemptively identify several ROS1 kinase domain point mutations that confer resistance to crizotinib and show that these crizotinibresistant ROS1 mutants remain sensitive to foretinib. These data suggest that foretinib may provide an alternative front-line treatment for ROS1-positive tumors and an effective second-line approach for patients that develop crizotinib-resistant disease.
Significance ROS1 fusion kinases are critical oncogenes in several malignancies, suggesting that ROS1 inhibitors are likely to be effective molecularly targeted therapies in these patients. Although phase I/II clinical trials using the ALK/ROS1 inhibitor crizotinib to treat ROS1 fusion-harboring non-small-cell lung cancer patients demonstrate early success, evidence of clinical resistance to crizotinib due to the acquired ROS1 G2032R mutation was recently reported. Here, we demonstrate that foretinib is a more potent ROS1 inhibitor than crizotinib in vitro and in vivo and remains effective against crizotinib-resistant ROS1 kinase domain mutations, including ROS1 G2032R. Taken together, our findings establish foretinib as a highly promising therapeutic candidate for treating patients with ROS1-driven malignancies and provide rationale for rapid clinical translation.
Author contributions: M.A.D., A.S., C.A.E., C.T., U.P.S., S.W.L., and B.J.D. designed research; M.A.D., A.S., C.A.E., C.T., R.L.S., J.E., A.A., and U.P.S. performed research; M.A.D., A.S., C.T., J.E., A.A., J.W.T., U.P.S., and S.W.L. contributed new reagents/analytic tools; M.A.D., A.S., C.T., R.L.S., and B.J.D. analyzed data; and M.A.D., A.S., C.A.E., C.T., J.E., J.W.T., S.W.L., and B.J.D. wrote the paper. Fig. 1 A and B) . Given current efforts to treat ROS1-driven cancers with ALK inhibitors (14) , we directly compared the efficacy of foretinib and Gö6976 to the previously known ALK inhibitors, crizotinib, TAE684, and GSK1838705A (15) (19) , as well as IL3-dependent Ba/F3 parental cells. Consistent with the results from the unbiased inhibitor screen, Ba/F3 cells expressing ROS1 fusions demonstrated superior sensitivity to foretinib, Gö6976, and TAE684 compared with crizotinib (Fig. 1B) . This finding was paralleled by a dose-dependent decrease in phosphorylation of ROS1 and its downstream effectors, SHP2 and ERK1/2 (Fig. 1C) . Conversely, the Ba/F3 BCR-ABL and JAK3
A572V -expressing cells as well as the parental cells were insensitive to foretinib, Gö6976, and ALK inhibitors, suggesting there is minimal toxicity of these compounds due to off-target effects (Fig. 1B) .
Among these inhibitors, foretinib and crizotinib are the only two compounds currently in clinical development. Although we found TAE684 and Gö6976 to also be potent ROS1 inhibitors, these are research-purpose compounds that do not have a clear path for clinical translation. As foretinib has an established safety and pharmacokinetic profile and is currently being evaluated in multiple phase I/II trials (20, 21) , we chose to restrict further analysis to the comparison of foretinib and crizotinib.
In NIH 3T3 cells transformed with FIG-ROS or SLC-ROS, foretinib more robustly suppressed ROS1 autophosphorylation as well as anchorage-independent colony formation compared with crizotinib ( Fig. S2 ). To determine whether these results could be recapitulated in human cancer cells, we exposed HCC78 cells, a NSCLC cell line expressing SLC-ROS, to increasing concentrations of foretinib or crizotinib. Consistent with our studies in Ba/F3 cells, foretinib inhibited the proliferation of HCC78 cells and abolished SLC-ROS and ROS1-effector protein phosphorylation at significantly lower doses than crizotinib ( Fig. 1 D and E) . Foretinib also showed greater efficacy than crizotinib in blocking colony formation ( Fig. 1F ) and migration of HCC78 cells (Fig. S3A ). By contrast, the overall selectivity of foretinib to block the growth of ROS1 fusion-driven NSCLC compared with other NSCLC cells was demonstrated by marked resistance of EGFR-driven NSCLC PC9 and HCC4011 cells to foretinib and crizotinib, but sensitivity to the EGFR inhibitor erlotinib, as expected (Fig. S3B) . Additionally, consistent with our Where indicated, **P < 0.01 and ***P < 0.001 by t test.
findings for Ba/F3 cells expressing activated ALK, human lymphoma cell lines harboring the NPM-ALK fusion (KARPAS-299 and SUDHL1) exhibited the expected response to crizotinib, but were relatively insensitive to foretinib. To further rule out the possibility that the inhibitory effect of crizotinib and foretinib on HCC78 cells might be due to their efficacy as MET inhibitors, we tested additional MET kinase inhibitors (MGCD-265, SGX-523, and JNJ38877605). HCC78 cells were insensitive to these compounds, implying that MET inhibition could not account for the effect of foretinib and crizotinib on these cells (Fig. S3C ). Fig. 2A) . In line with our data from Ba/F3 and HCC78 cells, foretinib was more potent than crizotinib at inhibiting cell proliferation. Foretinib, and to a lesser extent crizotinib, also significantly decreased the propensity of FIG-ROS but not shPten cholangiocarcinoma tumor cell lines to form anchorage-independent colonies in soft agar (Fig. 2B) . (Fig. 2C) .
Direct assessment of FIG-ROS signaling activity by immunoblot analysis revealed near complete inhibition of FIG-ROS auto-
Based Overall, these data demonstrate that foretinib is significantly more effective than crizotinib in blocking the growth of ROS1 fusion-driven cancers and highlights the potential for foretinib as a promising treatment for tumors carrying ROS1 fusions.
Crizotinib-Resistant ROS1 Mutants Remain Sensitive to Foretinib.
Despite the clinical benefit of molecularly targeted tyrosine kinase inhibitor therapies, development of therapeutic resistance remains a challenge. For example, acquisition of point mutations in the BCR-ABL and EGFR kinase domains that interfere with inhibitor binding frequently result in resistance to imatinib in chronic myeloid leukemia and to erlotinib in NSCLC, respectively (24, 25) . Whereas clinical data from the initial phase I trial using crizotinib to treat patients with ROS1-rearranged lung cancer are promising (9), a subset of these patients with crizotinib-treated ROS1 expression may become resistant to therapy, as observed for patients with ALK fusion-bearing lung cancer (26, 27) . To preemptively identify ROS1 kinase domain mutations conferring resistance to crizotinib, we performed an N-ethyl-N-nitrosourea (ENU)-assisted accelerated mutagenesis screen (28) using Ba/F3 FIG-ROS cells in the presence of increasing concentrations of crizotinib (500-2,500 nM). We observed a crizotinib concentration-dependent reduction in the percentage of wells with outgrowth, and the recovered clones were submitted for subsequent ROS1 kinase domain sequence analysis (Fig. S5 A and B) . Six different ROS1 kinase domain point mutations were identified either alone or in combination, the two most frequent being V2098I and G1971E (Fig. 4A) . Notably, all recovered clones remained sensitive to depletion of FIG-ROS by RNA interference, confirming that the ENU-based mutagenesis did not induce additional mutational events that confer FIG-ROS independence (Fig. S5C) .
To understand how these mutations might confer drug resistance, we constructed homology models of the ROS1 kinase domain bound to crizotinib and foretinib based on reported crystallographic data for crizotinib:ALK-and foretinib:METbound complexes (Fig. S5D) . The L1947R, L1982F, and V2098I mutations map close to structural features that are implicated in inhibitor binding (nucleotide binding loop, helix αC, and activation loop, respectively). Importantly, mutations of L1152 in ALK, a residue homologous to L1982 in ROS1, confer crizotinib resistance (29) and this mutation was recently identified in a patient with crizotinib-treated NSCLC with clinical resistance (26) . Also, DFG motif-proximal mutations in ALK exhibit increased resistance to crizotinib (29) . The mutations G1971E and C2060G map to locations that are distant to the inhibitor binding site in the N-terminal and C-terminal lobes, respectively. We generated each of the six most frequently recovered crizotinib-resistant mutants (V2098I, G1971E, L1982F, C2060G, L1947R, and E1935G) in Ba/F3 FIG-ROS cells and confirmed their ability to confer IL-3 independence similar to wild- type  FIG-ROS (Fig. S5E) . As expected, all tested FIG-ROS mutants exhibited increased resistance to crizotinib (IC 50 range: 350-2,450 nM; Fig. 4B and Fig. S6 A and C) . IC 50 values of the FIG-ROS mutants for crizotinib were close to or exceeded the clinically achievable maximum plasma concentration (411 ng/mL; 913 nM), suggesting that some of these mutants may be inefficiently inhibited at physiologically relevant concentrations. Notably, whereas the FIG-ROS kinase domain mutants exhibited slightly reduced sensitivity to foretinib (IC 50 range: 7-18 nM), all were inhibited at concentrations below the recently described safe and tolerated at clinically achievable plasma levels ( Fig. 4B and Fig. S6 B and C) (20, 30) . The differential sensitivity of these mutants to crizotinib was further supported by immunoblot analysis that showed decreased inhibition of FIG-ROS autophosphorylation in mutant compared with wild-type cells as well as foretinib-treated cells (Fig. S6D) .
While our manuscript was under review, therapeutic resistance to crizotinib in a patient with CD74-ROS-rearranged lung adenocarcinoma was reported, resulting from the acquisition of a G2032R kinase domain point mutation which precludes crizotinib binding due to steric hindrance (31) . To assess whether the G2032R mutation retained sensitivity to foretinib similarly to the ROS1 mutations recovered in the accelerated mutagenesis screen, we evaluated the efficiency of foretinib to suppress ROS1 phosphorylation and ROS1-dependent cell growth in stably transformed Ba/F3 CD74-ROS wild-type and G2032R mutant cell lines. Ba/F3 CD74-ROS G2032R cells were highly resistant to crizotinib (IC 50 : ∼2200 nM) compared with wild-type CD74-ROS (IC 50 : 14 nM) (Fig. 4C) . Despite being less sensitive to foretinib than the wild-type CD74-ROS fusion, the CD74-ROS G2032R mutant kinase remained sensitive to foretinib (IC 50 : 50 nM) at concentrations below plasma levels that can be safely achieved in patients with oral dosing. Thus, foretinib may offer an efficient second-line therapy in patients who are treatment refractory due to the acquisition of ROS1 mutations that confer resistance to crizotinib.
Discussion
The growing recognition of patients harboring ROS1 fusions as a distinct subgroup within multiple cancer entities provides impetus for the development of ROS1-directed therapeutic strategies. ROS1 fusions lead to constitutive kinase activation and can function either as dominant oncogenes or in cooperation with other genetic aberrations. Our overall goal was to take advantage of a high-throughput unbiased screening approach to identify small-molecule kinase inhibitors with potent activity against ROS1. Using this methodology, we found that foretinib is a highly effective inhibitor of ROS1 in human and murine model systems, demonstrating greater potency compared with crizotinib both in vitro and in vivo. To date, putative membrane-associated as well as cytoplasmic ROS1 fusions have been identified (5, 14).
Our cellular model systems consistently revealed reduced sensitivity of the putative membrane-associated SLC-ROS compared with cytoplasmic FIG-ROS, suggesting the intriguing possibility that subcellular localization may modulate inhibitor sensitivity for ROS1 fusions, which should be taken into consideration for future efforts directed at the development of novel ROS1 inhibitors. Despite the reported binding affinity (K d ) of crizotinib for ROS1 being lower than that of foretinib (4.4 nM and 14 nM, respectively; Dataset S2), we found foretinib to be a significantly more potent ROS1 inhibitor in cell-based assays, accentuating that the in vitro binding affinity does not directly translate to inhibitory efficacy in the cellular context. Thus, functional assays are indispensable for preclinical drug discovery of lead compounds. Whereas ALK inhibitors are at the forefront of ROS1-targeted therapy investigation, we note that the ALK inhibitor GSK1838705A does not effectively inhibit ROS1. These data highlight that not all ALK and ROS1 inhibitors exhibit unequivocal inhibitory reciprocity.
Emerging clinical data establish that the multikinase inhibitor crizotinib is an effective therapeutic agent in patients with lung adenocarcinoma harboring oncogenic ROS1 fusions (1, 7, 9, 31) . Even with these promising results from clinical trials evaluating crizotinib, previous experience with the clinical use of kinase inhibitors to treat cancer suggests that resistance is a common obstacle, frequently occurring through acquisition of mutations in the targeted kinase that interfere with drug binding and lead to reactivation of oncogenic signaling. Indeed, Awad et al. recently reported on clinical resistance to crizotinib in a patient with CD74-ROS-harboring lung adenocarcinoma that resulted in disease progression and death (31) . Sequencing of the pretreated and posttreatment tumor sample from this patient revealed the acquisition of a G2032R mutation in the ROS1 kinase domain that conferred resistance to crizotinib. Here we demonstrate that foretinib effectively inhibits the CD74-ROS G2032R mutant kinase (IC 50 : 50 nM) at clinically feasible concentrations. In an effort to further anticipate additional ROS1 kinase domain mutations that may confer resistance to crizotinib and test the inhibitory efficacy of foretinib in this context, we used a well-established in vitro cell-based accelerated mutagenesis screen. Crizotinib-resistant clones were recovered at concentrations up to 1,500 nM, which is above clinically achievable levels of this drug in patients, although each of these mutations alone was potently inhibited by foretinib (IC 50 s ≤ 20 nM) at physiologically relevant concentrations. Specifically, Eder et al. (30) report that the mean steady state C max of foretinib in patient plasma after administering the maximum tolerated dose of 3.6 mg/kg (median: 240 mg for 5 consecutive days every 2 wk) is 340 nM. In a second study with modified dose structure (80 mg once daily for 2 wk), the steady-state peak concentration was 46 ng/mL (72 nM) (20) . These previous pharmacokinetic studies of foretinib strongly suggest that this inhibitor is poised for further clinical evaluation for the treatment of ROS1-driven malignancies.
In conclusion, our results establish that foretinib is a significantly more potent ROS1 inhibitor compared with crizotinib. Recently, the FDA granted accelerated approval to crizotinib for ALK-positive, locally advanced or metastatic NSCLC. Our preclinical data suggest that foretinib may be similarly promising either as first-line therapy for cancer patients harboring ROS1 rearrangements or as a second-line approach for patients failing crizotinib therapy due to the acquisition of resistant mutations. produced from the WEHI-3 myelomonocytic IL-3 secreting cells. Ba/F3 cell lines were maintained at densities of 0.5 × 10 6 to 1.5 × 10 6 /mL and infected with retrovirus-encoding human FIG-ROS-S (indicated FIG-ROS) or SLC-ROS-S (indicated SLC-ROS) fusion genes. Stable cell lines were generated after sorting for GFP expression on a FACS Aria flow cytometer. Cells were counted daily using a Guava Personal Cell Analysis flow cytometer. NIH 3T3 cells (obtained from ATCC) were cultured in DMEM-high glucose medium supplemented with 10% FCS, L-glutamine, and penicillin/streptomycin. Early passage NIH 3T3 cells were infected with retrovirus and sorted for GFP expression as described for Ba/F3 cells. HCC78 cells [obtained from the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DMSZ) cell bank], were cultured in RPMI medium 1640 with 10% FBS, L-glutamine, and penicillin/ streptomycin; this media formulation is referred to as RPMI-10% FBS hereon. The commercially obtained cell lines were passaged no more than six times and used for fewer than 6 mo after receipt.
Cell Viability Assays. Cell lines were distributed in 96-well plates and incubated with escalating concentrations of inhibitors for 72 h. HCC78 and murine cholangiocarcinoma (mCC) cells were seeded at 12-18 h before adding inhibitors. The following cell densities were used: Ba/F3 cells -4 × 10 3 cells per well; HCC78 and mCC cells -1.5 × 10 3 cells per well. Cell viability was measured using a methanethiosulfonate (MTS)-based assay (CellTiter96 Aqueous One Solution; Promega) and absorbance (490 nm) was read at 30 min and 1 h after adding reagent using a BioTek Synergy 2 plate reader. To facilitate comparison between experiments, the raw MTS absorbance of vehicle (0.1% DMSO)-treated cells was set to 1 and absorbance from inhibitor-treated wells was normalized to the vehicle-treated value. Each experiment had a minimum of three replicate wells per condition and the average and SEM was plotted for curve fit analysis. Data were normalized using Microsoft Excel and further nonlinear regression curve fit analysis of the normalized data for determination of IC 50 values was performed using GraphPad Prism software.
Accelerated Cell-Based Mutagenesis Screen. Ba/F3 cells expressing FIG-ROS were treated overnight ENU (50 μg/mL), pelleted, resuspended in fresh media, and distributed into 96-well plates at a density of 1 × 10 5 cells per well in 200 μL complete media supplemented with crizotinib, ranging from 500 nM to 2,500 nM. The wells were observed for cell growth under an inverted microscope and media color change every 2 d for 1 mo. The contents of wells exhibiting cell outgrowth were transferred to a 24-well plate containing 2 mL RPMI-10% FBS media supplemented with crizotinib at the same concentration as in the initial 96-well plate. At confluency, cells in 24-well plates were collected by centrifugation. To focus on identification of mutations conferring high-level resistance to crizotinib, DNA was extracted from the cell pellets of expanded clones from 750 nM to 1,500 nM crizotinibtreated plates using a DNEasy Tissue kit (Qiagen); no outgrowth was observed in the number of wells surveyed at concentrations of 2,000 nM and above. The FIG-ROS kinase domain was amplified using primers FIG-ROS M13-Kin3F (5′ GTA AAA CGA CGG CCA GTG CGA GAC TAG CTG CCA AGT AC) and ROS M13-Kin1 Rev (5′ CAG GAA ACA GCT ATG ACC GCC ATC TTC ACC TTC AAA GC), and the PCR products were bidirectionally sequenced using M13F (5′ GTA AAA CGA CGG CCA GTG) and M13 Rev (5′ CAG GAA ACA GCT ATG ACC) primers. The chromatographs were analyzed for mutations using Mutation Surveyor software (SoftGenetics).
Statistical Analysis. Where indicated, the Student t test (Microsoft Excel or GraphPad Prism) was used to determine statistical significance and comparisons; P values less than 0.05 were deemed significant. Asterisks in figures and the description of asterisks in figure legends indicate level of statistical significance.
